Genentech, Inc.

University of California

F. Hoffmann-La Roche Ag

Joseph R Arron

Meredith C Hazen

Heleen Scheerens

Yanan Zheng

Richard W Erickson

Michelle Freemer

Guiquan Jia

John G Matthews

Wendy Putnam

Yan Wu

Wei-Ching Liang

Dhaya Seshasayee

Tracy Staton

John Vincent Fahy

Rajita Khosla

Brian Yaspan

Amy Dressen

Barmak Modrek

David F Choy

Meredith Hazen

Tulika Tyagi

Daryle Depianto

Thirumalai Rajan Ramalingam

Wendy Green Halpern

Jian Ping Yin

Jia Wu

Tianhe Sun

WeiYu Lin

David Choy

Vladimir Ramirez-Carrozzi

Sanjay Chandriani

Prescott Woodruff

Alexander R Abbas

Nicholas J I Lewin-Koh

Katrina B Morshead

The invention provides isoform-selective anti-TGFβ antibodies and methods of using the same. In particular, isoform-selective anti-TGFβ2, anti-TGFβ3, and anti-TGFβ2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGFβ-related disorders.

Isoform-selective anti-TGFβ antibodies and methods of use

The invention relates to methods of treating a patient suffering from an IL-33-mediated disorder, such as asthma, comprising administering to the patient an IL-33 axis binding antagonist based on the genotype of the /L1RL1gene, the genotype of a polymorphism in genomic vicinity to the IL-33 gene, the expression level of periostin or the expression level of soluble ST2. The invention further relates to methods of determining whether a patient is at increased risk of an IL-33-mediated disorder, as well as methods of determining whether a patient suffering from such a disorder is likely to respond to a treatment comprising an IL-33 axis binding antagonist, based on the genotype of the /L1RL1gene the genotype of a polymorphism in genomic vicinity to the IL-33 gene, the expression level of periostin or the expression level of soluble ST2.

Therapeutic and diagnostic methods for IL-33-mediated disorders

Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.

Method of treating asthma using an IL-13 antibody

Diagnosis and treatments relating to TH2 inhibition

Growing community of inventors

San Mateo, CA, United States of America

Joseph R Arron